Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Hamel

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|July 23, 2013
Germ-line and somatic DICER1 mutations in a pleuropulmonary blastomaLeanne de Kock, François Plourde, Melissa T Carter, et al.
Cancer|January 28, 2003
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up dataJohn R Goffin, Pierre O Chappuis, Louis R Bégin, et al.
Journal of Medical Genetics|January 18, 2022
Long-term tumour dormancy in a <i>BRCA1</i> heterozygoteSetor Amuzu, Lili Fu, Nadine Demko, et al.
Gastroenterology|July 29, 2009
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancerMarc D Tischkowitz, Nelly Sabbaghian, Nancy Hamel, et al.
Hereditary Cancer in Clinical Practice|September 17, 2014
Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, CanadaTaila Hartley, Luca Cavallone, Nelly Sabbaghian, et al.
BJC Reports|April 8, 2026
A comprehensive genomic framework for identifying genes predisposing to homologous recombination repair-deficient breast or ovarian cancerJosé Camacho-Valenzuela, Thibaut Matis, Carla Roca, et al.
Journal of Medical Genetics|November 2, 2010
Germline DICER1 mutations and familial cystic nephromaAmin Bahubeshi, Nebil Bal, Thomas Rio Frio, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2010
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
BMC Cancer|August 19, 2008
Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian womenDavid J Novak, Long Qi Chen, Parviz Ghadirian, et al.
Human Pathology|April 4, 2015
Ovarian embryonal rhabdomyosarcoma is a rare manifestation of the DICER1 syndromeLeanne de Kock, Harriet Druker, Evan Weber, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|July 23, 2013
Germ-line and somatic DICER1 mutations in a pleuropulmonary blastomaLeanne de Kock, François Plourde, Melissa T Carter, et al.
Cancer|January 28, 2003
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up dataJohn R Goffin, Pierre O Chappuis, Louis R Bégin, et al.
Journal of Medical Genetics|January 18, 2022
Long-term tumour dormancy in a <i>BRCA1</i> heterozygoteSetor Amuzu, Lili Fu, Nadine Demko, et al.
Gastroenterology|July 29, 2009
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancerMarc D Tischkowitz, Nelly Sabbaghian, Nancy Hamel, et al.
Hereditary Cancer in Clinical Practice|September 17, 2014
Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, CanadaTaila Hartley, Luca Cavallone, Nelly Sabbaghian, et al.
BJC Reports|April 8, 2026
A comprehensive genomic framework for identifying genes predisposing to homologous recombination repair-deficient breast or ovarian cancerJosé Camacho-Valenzuela, Thibaut Matis, Carla Roca, et al.
Journal of Medical Genetics|November 2, 2010
Germline DICER1 mutations and familial cystic nephromaAmin Bahubeshi, Nebil Bal, Thomas Rio Frio, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2010
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
BMC Cancer|August 19, 2008
Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian womenDavid J Novak, Long Qi Chen, Parviz Ghadirian, et al.
Human Pathology|April 4, 2015
Ovarian embryonal rhabdomyosarcoma is a rare manifestation of the DICER1 syndromeLeanne de Kock, Harriet Druker, Evan Weber, et al.
Pageof 7